about
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsProgrammed anuclear cell death delimits platelet life span.Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome primingPharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune diseaseIn vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasDisseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient.The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.Marked eosinophilia with abnormal basophilic granules in acute graft-versus-host disease post-allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without CBFB-MYH11 mutation.Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263).Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function.Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes.Go with the flow for monitoring response in myeloma with minimal residual disease
P50
Q27683708-FBCD21D1-601B-497B-9667-CE08109B0953Q33374664-C8C264FC-FF62-4CAA-A074-B8D2F9445112Q33395784-704477C7-75A0-4E8A-B445-02455309BD2DQ33397149-742FE404-A924-4AD6-9821-364677955DEFQ33934591-EC00A9E7-9A5B-4C85-AC21-29D9CC06F887Q34343275-490AC23D-7544-4F8A-953B-231A346DD3A9Q35678266-A25B2CD3-9951-4321-875A-D357B7586985Q36268587-185430FE-1017-4026-B41C-87A64F349746Q36616993-08735CCD-601E-4407-B006-76F8A7E0886FQ36970689-6DAE7468-1FEF-4A3B-9F11-8BA65C089067Q38070926-663D1948-8B31-49C5-B2E0-DA58AB186C98Q42064781-00689FB1-35ED-48E1-9261-405E6A8007EFQ44047466-4B9089A4-E030-4C8D-86A5-0F973F4E52AFQ44324471-9EC76B72-DC34-4F02-970D-F768C16F3F8FQ46040273-724E088F-76CF-4482-9164-19C79933F44AQ53183279-BA04900E-BBFE-4EF5-846B-F7D937848332Q55070749-119BD597-8C35-4DF4-9A8C-4081CFE224E7Q80579894-1106ED5B-FCE0-47F5-B3CC-B20DEA1AAAF7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kylie D Mason
@es
Kylie D. Mason
@en
Kylie D. Mason
@nl
Kylie D. Mason
@sl
type
label
Kylie D Mason
@es
Kylie D. Mason
@en
Kylie D. Mason
@nl
Kylie D. Mason
@sl
prefLabel
Kylie D Mason
@es
Kylie D. Mason
@en
Kylie D. Mason
@nl
Kylie D. Mason
@sl
P108
P106
P108
P1153
10440115200
P21
P31
P496
0000-0002-6238-4092
P569
2000-01-01T00:00:00Z